| Sedighi, Rashin |
INSITE-DME, NCT05610319: Treat & Extend Versus Fixed Dosing with Faricimab for Management of Diabetic Macular Edema: a Pragmatic, Multi-center, Open-label, Randomized, Controlled Trial |
|
|
| Active, not recruiting | 4 | 446 | Europe, Canada, US, RoW | Faricimab | McMaster University, Hoffmann-La Roche | Diabetic Macular Edema | 12/26 | 12/26 | | |
| Recruiting | 1/2 | 215 | US | 4D-150 IVT, Aflibercept IVT | 4D Molecular Therapeutics | Neovascular (Wet) Age-Related Macular Degeneration | 11/25 | 11/26 | | |
| Sheth, Veeral |
INSITE-DME, NCT05610319: Treat & Extend Versus Fixed Dosing with Faricimab for Management of Diabetic Macular Edema: a Pragmatic, Multi-center, Open-label, Randomized, Controlled Trial |
|
|
| Active, not recruiting | 4 | 446 | Europe, Canada, US, RoW | Faricimab | McMaster University, Hoffmann-La Roche | Diabetic Macular Edema | 12/26 | 12/26 | | |
| Recruiting | 2/3 | 497 | US | Dexamethasone ophthalmic suspension (OCS-01), Dexamethasone, Vehicle, Placebo | Oculis, ICON plc | Diabetic Macular Edema | 06/26 | 06/26 | | |
SIGLEC, NCT05839041: A Multiple Dose Study of AVD-104 for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) |
|
|
| Active, not recruiting | 2 | 300 | US | AVD-104, Avacincaptad | Aviceda Therapeutics, Inc. | Geographic Atrophy of the Macula, Macular Degeneration | 09/25 | 09/26 | | |
| Recruiting | 1/2 | 215 | US | 4D-150 IVT, Aflibercept IVT | 4D Molecular Therapeutics | Neovascular (Wet) Age-Related Macular Degeneration | 11/25 | 11/26 | | |
NCT05643118: Evaluation of OLX10212 in Patients With Neovascular Age-related Macular Degeneration |
|
|
| Recruiting | 1 | 42 | US | OLX10212 is a cell penetrating asymmetric small interference RNA (cp-asiRNA), OLX10212 | Olix Pharmaceuticals, Inc., Trial Runners, LLC | Neovascular Age-related Macular Degeneration | 11/24 | 12/24 | | |
| Active, not recruiting | N/A | 95 | US | i-Lumen(TM) AMD, i-Lumen(TM) AMD Sham | i-Lumen Scientific, Inc. | Age-Related Macular Degeneration, Dry Age-related Macular Degeneration, Nonexudative Age-related Macular Degeneration | 06/25 | 06/25 | | |
| Kirby, BreAnne |
Tejas, NCT05387837: Safety, Tolerability and PK of Subcutaneous D-4517.2 in Subjects With Wet AMD or DME |
|
|
| Active, not recruiting | 2 | 50 | US | D-4517.2, aflibercept | Ashvattha Therapeutics, Inc. | Neovascular Age-related Macular Degeneration, Diabetic Macular Edema | 11/24 | 12/24 | | |
| Recruiting | 1/2 | 215 | US | 4D-150 IVT, Aflibercept IVT | 4D Molecular Therapeutics | Neovascular (Wet) Age-Related Macular Degeneration | 11/25 | 11/26 | | |
NCT05643118: Evaluation of OLX10212 in Patients With Neovascular Age-related Macular Degeneration |
|
|
| Recruiting | 1 | 42 | US | OLX10212 is a cell penetrating asymmetric small interference RNA (cp-asiRNA), OLX10212 | Olix Pharmaceuticals, Inc., Trial Runners, LLC | Neovascular Age-related Macular Degeneration | 11/24 | 12/24 | | |
| Active, not recruiting | N/A | 11 | US | episcleral brachytherapy, Strontium 90 | Salutaris Medical Devices, Inc. | Macular Degeneration, Choroidal Neovascularization | 05/23 | 05/25 | | |
| Active, not recruiting | N/A | 95 | US | i-Lumen(TM) AMD, i-Lumen(TM) AMD Sham | i-Lumen Scientific, Inc. | Age-Related Macular Degeneration, Dry Age-related Macular Degeneration, Nonexudative Age-related Macular Degeneration | 06/25 | 06/25 | | |
| Danzig, Carl |
NCT05573100: The Study of CU06-1004 in Patients With Diabetic Macular Edema (DME) |
|
|
| Completed | 2 | 67 | US | CU06-1004, SAC-1004, CU06, CU06-RE | Curacle Co., Ltd., Théa Open Innovation, France | Diabetic Macular Edema | 05/23 | 06/23 | | |
ASPIRE, NCT06011798: Assess the Efficacy and Safety of Repeat Intravitreal Injections of Foselutoclax (UBX1325) in Patients With DME |
|
|
| Active, not recruiting | 2 | 52 | US | Aflibercept, foselutoclax, UBX1325 | Unity Biotechnology, Inc. | Diabetic Macular Edema, Retinal Disease, Macular Edema, Diabetes Mellitus, Diabetic Retinopathy, Retinal Degeneration, Retinal Diseases, Eye Diseases, Edema | 03/25 | 06/25 | | |
SIGLEC, NCT05839041: A Multiple Dose Study of AVD-104 for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) |
|
|
| Active, not recruiting | 2 | 300 | US | AVD-104, Avacincaptad | Aviceda Therapeutics, Inc. | Geographic Atrophy of the Macula, Macular Degeneration | 09/25 | 09/26 | | |
MAGNIFY, NCT05893537: Study to Evaluate the Efficacy and Safety of Oral CT1812 in Participants with Geographic Atrophy (GA) Secondary to Dry Age-Related Macular Degeneration (AMD). |
|
|
| Active, not recruiting | 2 | 100 | US | Active Comparator CT1812, Placebo Comparator | Cognition Therapeutics | Age-Related Macular Degeneration | 07/27 | 08/27 | | |
| Recruiting | 1/2 | 215 | US | 4D-150 IVT, Aflibercept IVT | 4D Molecular Therapeutics | Neovascular (Wet) Age-Related Macular Degeneration | 11/25 | 11/26 | | |
| Vallejo, Cindy |
INSITE-DME, NCT05610319: Treat & Extend Versus Fixed Dosing with Faricimab for Management of Diabetic Macular Edema: a Pragmatic, Multi-center, Open-label, Randomized, Controlled Trial |
|
|
| Active, not recruiting | 4 | 446 | Europe, Canada, US, RoW | Faricimab | McMaster University, Hoffmann-La Roche | Diabetic Macular Edema | 12/26 | 12/26 | | |
ReNEW, NCT06373731: Phase 3 Study of Efficacy, Safety & Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects With Dry Age-Related Macular Degeneration (Dry AMD) |
|
|
| Recruiting | 3 | 360 | Europe, US, RoW | Elamipretide, Elamipretide HCL, Placebo | Stealth BioTherapeutics Inc. | Age Related Macular Degeneration (ARMD) | 08/26 | 08/27 | | |
| Recruiting | 1/2 | 215 | US | 4D-150 IVT, Aflibercept IVT | 4D Molecular Therapeutics | Neovascular (Wet) Age-Related Macular Degeneration | 11/25 | 11/26 | | |
